Beckie Fenrick, Author at AlignRx

Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars

CVS Formulary Change – What You Need to Know CVS Caremark has announced the removal of Humira from some of their formularies starting the second quarter of 2024. The transition to biosimilar alternatives, which are part of the covered formulary, is planned. Key Points of the Announcement Impact Period: Starting April 1, 2024 Affected Parties: […]

Stay Informed, Stay Ahead: CVS’s Transition from Humira to Biosimilars Read More »

Levemir Discontinuation: What You Need to Know

Clinical Insights, Employer Groups & Consultants, News, Pharmacy Benefit Management / Beckie Fenrick

Novo Nordisk, a global healthcare company, has recently announced the discontinuation of Levemir, a long-acting insulin, in the United States. This significant development, announced in November 2023, is set to reshape the landscape for many relying on this medication. Key Points of the Announcement: Impact Period: Expected to commence in January 2024 and span through

Levemir Discontinuation: What You Need to Know Read More »

Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions

Clinical Insights, Pharmacy Benefit Management / Beckie Fenrick

The ever-evolving pharmaceutical landscape is no stranger to reforms and regulations. With the recent changes brought about by the American Rescue Plan (ARP) of 2021, both Pharmacy Benefit Managers (PBMs) and Drug Manufacturers are adjusting their strategies. This article dives deep into these shifts and the subsequent reactions from industry stakeholders. Market Events and their

Medicaid AMP Cap Removal: Market Changes & Rx Strategies Amidst New Provisions Read More »

The Cost Implications of New Weight Loss Treatments for Plan Sponsors

Clinical Insights, Employer Groups & Consultants, Insights for Health Plans, Uncategorized / Beckie Fenrick

See this article by AlignRx chief pharmacy officer Beckie Fenrick as it originally appeared in BenefitsPRO. With obesity rates in the United States having tripled since the 1980s, the health care system now faces an annual cost of $173 billion due to obesity-related complications, such as heart disease, hypertension, joint pain and certain types of

The Cost Implications of New Weight Loss Treatments for Plan Sponsors Read More »

What Brokers and TPAs Need To Know About Humira Biosimilars

Clinical Insights, Insights for Health Plans, News / Beckie Fenrick

Below is an excerpt from an article by AlignRx chief pharmacy officer Beckie Fenrick and Goodroot area vice president of business development Brian Shonat that was recently published in BenefitsPRO. Following decades of patent litigation and maneuvering, the first biosimilar to Humira is now available with many more to follow this year. Humira is a

What Brokers and TPAs Need To Know About Humira Biosimilars Read More »

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars

Clinical Insights, Insights for Health Plans, News / Beckie Fenrick

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »

Prediabetes and Type 2 Diabetes Screening

Clinical Insights, Employer Groups & Consultants / Beckie Fenrick

What is happening: In August 2021 the United States Preventive Services Task Force (USPSTF) recommended that adults, aged 35 to 70 years who are overweight or obese, be screened for prediabetes or type 2 diabetes. In addition to these screenings, USPSTF recommended that clinicians should offer patients with prediabetes effective preventive interventions. Preventive interventions include

Prediabetes and Type 2 Diabetes Screening Read More »

What Employers, TPAs and Brokers Need to Know About COVID 10 Home Testing

Clinical Insights, Employer Groups & Consultants / Beckie Fenrick

January 10, 2022, the U.S. Department of Labor (DOL) issued guidance related to insurance coverage for COVID OTC testing, provided at no cost to covered individuals that was effective as of January 15, 2022. COVID 10 Home Testing Highlights Beginning January 15, 2022, most individuals with health insurance can purchase at home over-the-counter COVID-19 diagnostic

What Employers, TPAs and Brokers Need to Know About COVID 10 Home Testing Read More »

How Digital Therapeutics Are Paid For Has Huge Implications

Clinical Insights / Beckie Fenrick

Digital Therapeutics (DTx) have been increasingly popular since smartphones and wearable tech have become ubiquitous. The pandemic has set them on a trajectory for massive growth and mainstream adoption. Currently, there is inconsistency in how DTx are handled by payers and health plans. We are at a critical juncture to set precedents that make sense

How Digital Therapeutics Are Paid For Has Huge Implications Read More »

Beckie Fenrick

Featured Content